RecruitingHepatocellular Carcinoma
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
Sponsor: Myeloid Therapeutics
You may qualify if…
- ✓ Aged 18 years or older
- ✓ Histological diagnosis of advanced/recurrent or metastatic and/or unresectable HCC. \[Note: participants with other tumor types expressing GPC3 may be eligible for Module 1 pending a discussion with the Medical Monitor. Only participants with HCC are eligible for Module 2.
- ✓ Measurable lesion per RECIST 1.1 criteria
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- ✓ Child-Pugh score: Class A
- ✓ Adequate organ function
- ✓ General Exclusion Criteria
- ✓ Known active CNS metastasis and/or carcinomatous meningitis.
Source: ClinicalTrials.gov · NCT06478693 · last updated 2025-12-18